# Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

> **NCT02358889** · PHASE2 · COMPLETED · sponsor: **Iconic Therapeutics, Inc.** · enrollment: 88 (actual)

## Conditions studied

- Choroidal Neovascularization
- Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** hI-con1
- **BIOLOGICAL:** ranibizumab
- **OTHER:** Sham injection

## Key facts

- **NCT ID:** NCT02358889
- **Lead sponsor:** Iconic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2020-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02358889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02358889, "Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02358889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*